Elite Pharmaceuticals (STU:ETF) Long-Term Debt : €3.04 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals Long-Term Debt?

Elite Pharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2023 was €3.04 Mil.

Elite Pharmaceuticals's quarterly Long-Term Debt declined from Jun. 2023 (€3.30 Mil) to Sep. 2023 (€3.14 Mil) and declined from Sep. 2023 (€3.14 Mil) to Dec. 2023 (€3.04 Mil).

Elite Pharmaceuticals's annual Long-Term Debt declined from Mar. 2021 (€1.46 Mil) to Mar. 2022 (€1.26 Mil) but then increased from Mar. 2022 (€1.26 Mil) to Mar. 2023 (€3.33 Mil).

Elite Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Elite Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Long-Term Debt Chart

Elite Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Debt

Get a 7-Day Free Trial

2.94

1.63

1.46

1.26

3.33

Elite Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															14.62	3.33	3.30	3.14	3.04

Elite Pharmaceuticals (STU:ETF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Elite Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals (STU:ETF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ELTP:USA

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines